--- title: "SERA PROGNOSTICS, INC. (SERA) stock and investor profile" url: "https://aibio.space/companies/sera-prognostics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "SERA PROGNOSTICS, INC. (NASDAQ: SERA), United States. Listing facts, related biotech companies and news on aibio.space." --- SERA SERA PROGNOSTICS, INC. NASDAQ · United States # SERA PROGNOSTICS, INC. (SERA) news SERA PROGNOSTICS, INC. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SERA, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. ## Latest SERA PROGNOSTICS, INC. news We have not published a story on SERA PROGNOSTICS, INC. yet. When there is news, it will appear here. ## SERA PROGNOSTICS, INC. at a glance - **Ticker**: SERA - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $46.4 million ### Related companies - [Lucid Diagnostics](https://aibio.space/companies/lucid-diagnostics/) NASDAQ: LUCD - [Ascend Wellness Holdings](https://aibio.space/companies/ascend-wellness/) OTC: AAWH - [WEST PHARMACEUTICAL SERVICES INC](https://aibio.space/companies/west-pharmaceutical-services/) NYSE: WST - [Mobia Medical](https://aibio.space/companies/mobia-medical/) NASDAQ: MOBI - [BullFrog AI Holdings](https://aibio.space/companies/bullfrog-ai/) NASDAQ: BFRG - [Penumbra](https://aibio.space/companies/penumbra/) NYSE: PEN - [FAMILY OFFICE OF AMERICA, INC.](https://aibio.space/companies/family-office-of-america/) OTC: FOFA - [CANNAPHARMARX, INC.](https://aibio.space/companies/cannapharmarx/) OTC: CPMD ### Also on NASDAQ - [Opus Genetics](https://aibio.space/companies/opus-genetics/) IRD - [Abeona Therapeutics](https://aibio.space/companies/abeona-therapeutics/) ABEO - [Filana Therapeutics](https://aibio.space/companies/filana-therapeutics/) FLNA - [SciSparc](https://aibio.space/companies/scisparc/) SPRC - [Vera Therapeutics](https://aibio.space/companies/vera-therapeutics/) VERA - [Gyre Therapeutics](https://aibio.space/companies/gyre-therapeutics/) GYRE ## SERA PROGNOSTICS, INC. annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$81,000](https://www.sec.gov/Archives/edgar/data/1534969/000153496926000009/) | [$77,000](https://www.sec.gov/Archives/edgar/data/1534969/000153496926000009/) | | Research and development | [$13.2 million](https://www.sec.gov/Archives/edgar/data/1534969/000153496926000009/) | [$14.7 million](https://www.sec.gov/Archives/edgar/data/1534969/000153496926000009/) | | Net income (loss) | [-$31.9 million](https://www.sec.gov/Archives/edgar/data/1534969/000153496926000009/) | [-$32.9 million](https://www.sec.gov/Archives/edgar/data/1534969/000153496926000009/) | | Cash from operations | [-$25.6 million](https://www.sec.gov/Archives/edgar/data/1534969/000153496926000009/) | [-$14.2 million](https://www.sec.gov/Archives/edgar/data/1534969/000153496926000009/) | | Cash and equivalents | [$3.9 million](https://www.sec.gov/Archives/edgar/data/1534969/000119312526346862/) | [$4.0 million](https://www.sec.gov/Archives/edgar/data/1534969/000153496926000009/) | | Short-term investments | [$35.3 million](https://www.sec.gov/Archives/edgar/data/1534969/000119312526346862/) | [$42.2 million](https://www.sec.gov/Archives/edgar/data/1534969/000153496926000009/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $4.4 million, plus short-term investments of $42.0 million, $46.4 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about SERA PROGNOSTICS, INC. What is the ticker symbol of SERA PROGNOSTICS, INC.? SERA PROGNOSTICS, INC. trades under the ticker SERA on NASDAQ. Where is SERA PROGNOSTICS, INC. listed? SERA PROGNOSTICS, INC. is listed on NASDAQ. Which country or territory is SERA PROGNOSTICS, INC. listed under? Our directory records SERA PROGNOSTICS, INC. under United States. Does aibio.space cover SERA PROGNOSTICS, INC.? aibio.space lists SERA PROGNOSTICS, INC. among 2,820 public biotech companies and publishes its news here as stories appear. What was SERA PROGNOSTICS, INC.'s revenue last year? $81,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is SERA PROGNOSTICS, INC. profitable? SERA PROGNOSTICS, INC. reported a net loss of $31.9 million for the fiscal year ended Dec 31, 2025, and used $25.6 million of cash in operations, per its annual report to the SEC. How much does SERA PROGNOSTICS, INC. spend on research and development? $13.2 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does SERA PROGNOSTICS, INC. have? $46.4 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. ## Investor discussion: SERA PROGNOSTICS, INC. Members talk about SERA PROGNOSTICS, INC. (SERA). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:SERA on TradingView](https://www.tradingview.com/symbols/NASDAQ-SERA/). ## Listing details SERA PROGNOSTICS, INC. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker SERA, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: SERA PROGNOSTICS, INC. - **Ticker**: SERA - **Listing**: NASDAQ - **Country or territory**: United States Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/sera-prognostics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "SERA PROGNOSTICS, INC. (SERA) stock and investor profile", 2026-10-31, https://aibio.space/companies/sera-prognostics/